Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244841 | 0.91 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL5249197 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL5249554 | 0.85 | SLC6A2 (0.83) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL5290070 | 0.83 | SLC6A2 (0.81) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL11792580 | 0.83 | SLC6A4 (0.76) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL11803430 | 0.81 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL5244478 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6HRH3 | |
| SCHEMBL5246173 | 0.81 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL12633242 | 0.81 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL1120086 | 0.81 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827435-A2 | 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | AMR Technology, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006057950-A2 | 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-06-01 | — | — | WO | claimed |
| US-20060111396-A1 | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | AMR TECHNOLOGY, INC. (US) | 2006-05-25 | — | — | US | claimed |
| US-20060111393-A1 | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | ALBANY MOLECULAR RESEARCH, INC. | 2006-05-25 | — | — | US | claimed |
| US-20040248933-A1 | Use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence | PHARMACIA & UPJOHN COMPANY | 2004-12-09 | — | — | US | claimed |
| EP-1827435-A2 | 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | AMR Technology, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7163949-B1 | 4-phenyl substituted tetrahydroisoquinolines and use thereof | AMR TECHNOLOGY, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| WO-2006057950-A2 | 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060111396-A1 | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | AMR TECHNOLOGY, INC. (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060111393-A1 | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | ALBANY MOLECULAR RESEARCH, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20040248933-A1 | Use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence | PHARMACIA & UPJOHN COMPANY | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248933-A1 | Use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence | SDHA, INA, PAH | SLC6A4 145/4885SLC6A2 114/4885SLC6A3 314/4885 |
| US-20060111396-A1 | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | SLC6A2, SLC18A2, SLC6A4 | SLC6A4 3/4885SLC6A2 1/4885SLC6A3 4/4885 |
| US-20060111393-A1 | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | SLC6A2, SLC18A2, SLC6A4 | SLC6A4 3/4885SLC6A2 1/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.